SMAD4 and neoplasm: In addition, further analyses are warranted, such as analyzing the subtypes of metastatic lesions and their correlation with treatment response, exploring the dynamic changes of tumor subtypes and immune profiles during treatment, and analyzing other biomarkers like tumor mutational burden, microsatellite instability/mismatch repair status, and SMAD4 gene alterations at baseline.